Literature DB >> 19713832

A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis.

Xuewei Zhuang1, Xiyan Xia, Chuanxin Wang, Fei Gao, Ningning Shan, Lei Zhang, Lining Zhang.   

Abstract

We investigated the number of intratumoral tumor-infiltrating lymphocytes (TILs), including CD4(+), CD8(+), and CD25(+) T cells, in nonsmall cell lung cancers (NSCLC) and their correlation with patient survival time. Tumor specimens from 30 NSCLC patients were consecutively obtained during surgery. Patient survival status was monitored. Based on survival time, patients were divided into 2 groups: 5-year survival group and 5-year nonsurvival group. CD4(+), CD8(+), and CD25(+) T cells that infiltrated tumors were detected and counted by immunohistochemistry. Patients with a lower number of TILs and CD8(+) T cells showed significantly shorter survival time compared with those with a higher number (P < 0.05). However, the number of CD4(+) and CD25(+) T cells in tumors was not correlated with survival time in patients with NSCLC (P > 0.05). These data demonstrate that high numbers of CD8(+) T cells among TILs is a strong indicator for a favorable clinical outcome.

Entities:  

Mesh:

Year:  2010        PMID: 19713832     DOI: 10.1097/PAI.0b013e3181b6a741

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  25 in total

1.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

Review 2.  Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

Authors:  D E Meyers; P M Bryan; S Banerji; D G Morris
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

Review 3.  Non-small cell lung cancer: current treatment and future advances.

Authors:  Cecilia Zappa; Shaker A Mousa
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.

Authors:  Joseph M Obeid; Nolan A Wages; Yinin Hu; Donna H Deacon; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-10-21       Impact factor: 6.968

Review 5.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

6.  Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression.

Authors:  Limo Chen; Xiaohui Yi; Sangeeta Goswami; Young-Ho Ahn; Jonathon D Roybal; Yongbin Yang; Lixia Diao; Di Peng; David Peng; Jared J Fradette; Jing Wang; Lauren A Byers; Jonathan M Kurie; Stephen E Ullrich; F Xiao-Feng Qin; Don L Gibbons
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

7.  Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Authors:  Edwin R Parra; Carmen Behrens; Jaime Rodriguez-Canales; Heather Lin; Barbara Mino; Jorge Blando; Jianjun Zhang; Don L Gibbons; John V Heymach; Boris Sepesi; Stephen G Swisher; Annikka Weissferdt; Neda Kalhor; Julie Izzo; Humam Kadara; Cesar Moran; Jack J Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2016-06-01       Impact factor: 12.531

Review 8.  Targeting the immune system in the treatment of non-small-cell lung cancer.

Authors:  Deepa Rangachari; Julie R Brahmer
Journal:  Curr Treat Options Oncol       Date:  2013-12

9.  Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Authors:  Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2015-02-03       Impact factor: 11.816

Review 10.  Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Authors:  C Zielinski; S Knapp; C Mascaux; F Hirsch
Journal:  Ann Oncol       Date:  2013-02-07       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.